Celldex Therapeutics (CLDX) +6.1% premarket after announcing positive three-year survival data for its rindopepimut Phase 2 clinical program. Data suggests "a substantial and continuing survival benefit in comparison to independent control datasets," and strongly supports an ongoing Phase 3 clinical program, CLDX says.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Tue, 8:23AM)
at Zacks.com (Mon, 5:00PM)
at Benzinga.com (Mon, 11:33AM)
at Nasdaq.com (Jan 26, 2015)
at CNBC.com (Nov 17, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs